Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
1994-2-2
pubmed:abstractText
Ursodeoxycholic acid (UDCA) is a hydrophilic biliary acid that has been used in the medical therapy of cholelithiasis. In the last decade, its use in the treatment of some liver diseases renewed the interest on its hepato-protective properties. Controlled trials have demonstrated that UDCA has symptomatic and laboratory beneficial effects in primary biliary cirrhosis and sclerosing cholangitis. However its effects on the long-term and patients survival have not been determined. Uncontrolled trials on the effects of UDCA on a series of cholestatic liver diseases (cystic fibrosis, chronic hepatitis, cholestasis of pregnancy, etc) have communicated promising results that require confirmation with methodologically rigorous studies. The research in this area has significantly stimulated the study of the mechanisms of cellular injury associated to cholestatic phenomena and its prevention or attenuation with UDCA. The present review analyzes the most outstanding aspects of UDCA mechanisms of action, pharmacology and clinical efficacy in the treatment of liver diseases.
pubmed:language
spa
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0034-9887
pubmed:author
pubmed:issnType
Print
pubmed:volume
121
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
439-46
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1993
pubmed:articleTitle
[Ursodeoxycholic acid in the treatment of cholestatic liver diseases].
pubmed:affiliation
Departamento de Gastroenterología, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago de Chile.
pubmed:publicationType
Journal Article, English Abstract, Review, Research Support, Non-U.S. Gov't